摘要
目的探讨胸腺肽α_1用于治疗重症肺炎的效果。方法将56例重症肺炎患者按随机数字表法分为治疗组和对照组,各28例。两组患者入院后均给予常规治疗,治疗组在上述基础上皮下注射1.6 mg胸腺肽α_1,1次/d,持续7 d,分别检测治疗前、治疗第7天患者免疫细胞水平、C反应蛋白((;RP】、血清降钙素原(PCT)、血白细胞计数(WBC)水平的变化。结果两组患者CRP、PCT、WBC和CD8^+较治疗前明显下降(P<0.05),CD4^+、CD4^+/CD8^+比值较治疗前有明显升高;治疗组各指标与对照组比较,差异有统计学意义(P<0.05);治疗组机械通气时间和入住ICU时间明显较对照组短(P<0.05)。结论在常规治疗的基础上使用胸腺肽α_1能提高重症肺炎患者的细胞免疫功能,改善炎症指标,缩短机械通气时间、入住ICU时间。
Objective To assess the efficacy of thymosin- α1 for patients with severe pneumonia. Methods Fifty- six patients with severe pneumonia were randomly divided into therapy group （n=28） and the control group （n=28）. Patients in both groups were treated with routine method, patients in therapy group received subcutaneous injection of 1.6 mg thymosin- α1 daily for 7 days. Cel ular immune function , white blood cel count（WBC）, serum C- reactive protein（CRP） and procalcitonin（PCT） levels were measured in both groups. Results In both groups CD4^＋,CD4^＋/CD8^＋were significantly increased and CRP, PCT, WBC and CD8＋ were decreased （P〈0.01） after treatment. The improvement of CD4^＋,CD4^＋/CD8^＋, CRP, PCT,WBC and CD8^＋ in therapy group were more markedly than that in control group（all P〈0.01）. Conclusion Thymosin- α1 can improve immune function and the prognosis in patients with severe pneumonia.
出处
《浙江医学》
CAS
2015年第9期738-740,共3页
Zhejiang Medical Journal
基金
义乌市医学重点学科建设资助(13-ZD03)
关键词
胸腺肽Α1
重症肺炎
临床观察
Thymosin alpha 1
Severe pneumonia
Clinical observation
